Lerodalcibep-liga, a once-monthly PCSK9 inhibitor, significantly reduces LDL-C in hypercholesterolemia, including HeFH, with ...

LIB Therapeutics has scored an FDA approval for its cholesterol-lowering, third-generation PCSK9 inhibitor, lerodalcibep-liga ...

A privately held biopharmaceutical company based in the United States. Its development and planned commercialization ...

The FDA approved Lerochol, a monthly PCSK9 inhibitor, for adults with hypercholesterolemia to reduce LDL-C levels alongside diet and exercise.

Once monthly proprotein convertase subtilisin/kexin type 9 (PCSK9) therapy has moved into a new phase with Food and Drug ...

Findings showed the trial met the primary endpoint, with enlicitide demonstrating a statistically significantly meaningful reduction in LDL-C compared with placebo. Topline data were announced from a ...

A greater reduction LDL-C was seen for combo therapy; reductions also seen in all-cause mortality, major adverse CV events, stroke incidence. HealthDay News — Combination lipid-lowering therapy (LLT) ...

FDA has announced the approval of LIB Therapeutics’ Lerochol (lerodalcibep-liga) for subcutaneous (SC) use as an adjunct to ...

In patients with cardiovascular disease or who are at high risk for CVD, lerodalcibep significantly decreases LDL-C. Lerodalcibep significantly decreases low-density lipoprotein cholesterol (LDL-C) in ...

Many randomized trials have established that the risk reduction for cardiovascular (CV) disease is proportional to the absolute reduction of low-density-lipoprotein cholesterol (LDL-C). Nevertheless, ...

Atherogenic lipoprotein particles can vary considerably in their cholesterol content, but each particle contains only one molecule of apoB-100 (or simply apoB). As a result, serum concentration of ...

LDL-C is considered to be the major lipid risk factor and the main target of lipid-lowering therapy. Nevertheless, as all potentially atherogenic lipoprotein particles contain only one molecule of ...